Clinical Trials Logo

Motor Neuron Disease clinical trials

View clinical trials related to Motor Neuron Disease.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05949294 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Start date: January 2024
Phase: Phase 1
Study type: Interventional

In this Phase 1 adult symptomatic patients with amyotrophic lateral sclerosis (ALS) carrying a superoxide dismutase 1 (SOD1) gene mutation thought to be causative of ALS, will receive single ascending doses of ARO-SOD1 administered by intrathecal (IT) infusion. The study is primarily intended to evaluate safety, but will also evaluate the effect of ARO-SOD1 on SOD1 cerebrospinal fluid (CSF) levels as a biomarker of pharmacodynamic (PD) effect, therefore lumbar punctures will be required at timepoints throughout the study. After each participant has completed their individual final visit, participants whose SOD1 CSF levels have recovered to a satisfactory level may rescreen and enroll into higher dose cohorts; or if unable or unwilling to rescreen may enroll into an open-label study to be added by amendment when supported by nonclinical data for multidose administration.

NCT ID: NCT05830214 Withdrawn - Healthy Clinical Trials

Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS

Start date: January 2024
Phase:
Study type: Observational

This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.

NCT ID: NCT05041114 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

The Synchron Motor Neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. The device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.

NCT ID: NCT04505358 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

ALS
Start date: January 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2a, randomized, double-blind, placebo-controlled pilot study to assess the biological activity, safety and pharmacokinetics of PU-AD compared to placebo in ALS. It will be conducted in approximately 20 sites in the US. Approximately 30 subjects will be enrolled in this study; subjects will be randomized 3:2 to receive either PU-AD 30 mg or matching placebo qd, added onto any current stable background treatment.

NCT ID: NCT04468191 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Fatigue in Patients With Amyotrophic Lateral Sclerosis

Start date: February 10, 2021
Phase: N/A
Study type: Interventional

Expiratory muscle strength training (EMST) is an emerging palliative intervention for prolonging pulmonary and swallow function in patients with amyotrophic lateral sclerosis (PALS), but it is unknown whether EMST may result in detrimental immediate to short-term fatigue because there is no way to measure fatigue non-invasively. This study will determine the immediate to short-term impact of EMST on objective respiratory and swallow function, whether subjective ratings of dyspnea and fatigue map to objective decompensation of respiratory and swallow function, and the ability to monitor fatigue of the respiratory and swallowing musculature non-invasively. Findings from this research study will provide preliminary evidence regarding optimal timing for PALS to complete EMST and will provide PALS and clinicians increased capabilities to monitor fatigue non-invasively.

NCT ID: NCT04390386 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Controlled Study of IC14 for Treatment of ALS

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

The ALS IC14 Trial is a multi-center, placebo-controlled clinical trial evaluating the safety and efficacy of IC14 for the treatment of ALS

NCT ID: NCT04055532 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Biomarkers in Neurodegenerative Diseases

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

NCT ID: NCT03892863 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis

Start date: November 15, 2019
Phase: N/A
Study type: Interventional

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms. Available treatment can prolong the disease duration but cannot modify the disease course. Depression is a frequent complication of ALS, which further decreases quality of life and the available data concerning effectivity of antidepressant drugs are conflicting. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity with confirmed antidepressive effect. The purpose of this study is to compare the effectiveness of rTMS in improving the depression in patients with ALS with placebo stimulation. Intervention will include 10 daily sessions. In each session 3000 magnetic pulses will be administered over the left dorsolateral prefrontal cortex. Assessment depression severity will be made before and after therapy, as well as two and four weeks later.

NCT ID: NCT03892382 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis

Start date: November 15, 2019
Phase: N/A
Study type: Interventional

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms. Available treatment can prolong the disease duration but cannot modify the disease course. Apathy is a frequent complication of ALS, affecting up to 30% of patients and affecting negatively the survival. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity with confirmed beneficial effect on apathy in several neurologic and psychiatric conditions. The purpose of this study is to compare the effectiveness of rTMS in improving the apathy in patients with ALS with placebo stimulation.

NCT ID: NCT03843710 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

REPAIR-ALS
Start date: March 2020
Phase: Phase 2
Study type: Interventional

REPAIR-ALS is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Amyotrophic Lateral Sclerosis (ALS) within twelve (12) months of Screening. The primary endpoint is the ratio of the oxidized to reduced form of nicotinamide adenine dinucleotide (NAD+:NADH) measured non-invasively by 31phosphorous magnetic resonance spectroscopy (31P-MRS).